Medigene Ag

Other

Fougera Pharmaceuticals Inc.

Irene Gander-Meisterernst

Yunik Chang

Robert Lathrop

Ulrich Moebius

Regina Greger

Johanna Holldack

Erwin Böhm

Erwin Bohm

Martin Rohrbach

Barbara Nave

John Nieland

The invention relates to a medicament containing a compound of general formula (I), where R=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, particularly a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, R=independently, a straight or branched C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, in particular a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, a &#x2014;[CH&#x2014;(CH)m-O]H group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a &#x2014;CH&#x2014;[CH&#x2014;(OH)][CH&#x2014;R]&#x2014; group, where R=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.

Medicament for the treatment of viral skin and tumour diseases

The invention relates to a medicament containing a compound of general formula (I), where R=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, particularly a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, R=independently, a straight or branched C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, in particular a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, a &#x2014;[CH&#x2014;(CH)m-O]H group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a &#x2014;CH&#x2014;[CH&#x2014;(OH)][CH&#x2014;R]- group, where R=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.

The invention relates to a medicament containing a compound of general formula (1), where R=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C-Calkyl, alkylene or alkynyl group, preferably a C-Calkyl, alkylene or alkynyl group, particularly a C-Calkyl, alkylene or alkynyl group, most preferably a Calkyl group, R2=independently, a straight or branched C-Calkyl, alkylene or alkynyl group, preferably a C-Calkyl, alkylene or alkynyl group, in particular a C-Calkyl, alkylene or alkynyl group, most preferably a Calkyl group, a &#x2014;[CH&#x2014;(CH)&#x2014;O]H group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a &#x2014;CH&#x2014;[CH&#x2014;(OH)][CH&#x2014;(R)]&#x2014; group, where R=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof. 

The invention relates to a method of preventing and/or treating a chronic and/or an atopic skin disease by administering an inhibitor of fatty acid oxidation to a patient in a pharmacologically effective amount. Furthermore, the invention relates to the use of at least one inhibitor of fatty acid oxidation for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of a chronic and/or an atopic skin disease.

Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases

Growing community of inventors

Stockdorf, Germany

Irene Gander-Meisterernst